Zusammenfassung
Das Verständnis der pharmakologischen Grundlagen der Psychopharmakotherapie ermöglicht es zum einen, neue Forschungsansätze auf dem Gebiet der psychiatrischen Pharmakotherapie nachzuvollziehen. Zum anderen erleichtern diese Kenntnisse für den klinisch tätigen Arzt eine adäquate und rationale Auswahl der von ihm verwendeten Pharmaka unter Einbeziehung der pharmakologischen und pharmakokinetischen Eigenschaften. Durch die Kenntnis des Wirkmechanismus und des Abbauweges des gewählten Pharmakons können darüber hinaus unerwünschte Arzneimittelwirkungen vorausgesehen und nach Möglichkeit vermieden werden.
Similar content being viewed by others
Literatur
Ampuero E, Rubio FJ, Falcon R et al (2010) Chronic fluoxetine treatment induces structural plasticity and selective changes in glutamate receptor subunits in the rat cerebral cortex. Neuroscience 169:98–108
Benkert O, Hippius H (2015) Kompendium der Psychiatrischen Pharmakotherapie, 10. Aufl. Springer, Berlin/Heidelberg/New York/Tokio
Berton O, Nestler EJ (2006) New approoaches to antidepressant drug discovery: beyond monoamines. Nat Rev Neurosci 7:137–151
Breimer DD (1984) Die Pharmakokinetik der Benzodiazepine. In: Kubicki S (Hrsg) Schlafstörungen in Abhängigkeit vom Lebensalter. Med. Wiss. Buchreihe der Schering AG Berlin, Bergkamen, S 13–22
Breitenstein B, Brückl TM, Ising M, Müller-Myhsok B, Holsboer F, Czamara D (2015) ABCB1 gene variants and antidepressant treatment outcome: a meta-analysis. Am J Med Genet B Neuropsychiatr Genet 168B(4):274–283
Chen ACH, Shirayama Y, Shin KH, Neve RL, Duman RS (2001) Expression of the cAMP response element binding protein (CREB) in hippocampus produces an antidepressant effect. Biol Psychiatry 49:753–762
Chuang D-M, Priller J (2006) Potential use of lithium in neurodegenerative disorder. In: Bauer M, Grof P, Müller-Oerlinghause B (Hrsg) Lithium in neuropsychiatry. The comprehensive guide. Informa UK, Abingdon
Cooper JE, Bloom FE, Roth RH (1996) The biochemical basis of neuropharmacology, 7. Aufl. Oxford University Press, Oxford/New York
Couillard-Despres S, Wuertinger C, Kandasamy M et al (2009) Ageinge abolishes the effects of fluoxetine on neurogenesis fluoxetine and neurogenesis during ageing. Mol Psychiatry 14:856–864
Cowen PJ (2008) Serotonin and depression: pathophysiological mechanism or marketing myth? Trends Pharmacol Sci 29(9):433–436
Duman RS (2014) Pathophysiology of depression and innovative treatments: remodelling glutamatergic synaptic connections. Dialogues Clin Neurosci 16:11–27
Duman RS, Heninger GR, Nestler EJ (1997) A molecular and cellular theory of depression. Arch Gen Psychiatry 54:597–606
Duman RS, Malberg J, Thorne J (1999) Neural plasticity to stress and antidepressant treatment. Biol Psychiatry 46:1181–1191
Duncan GE, Johnson KB, Breese GR (1993) Topographic patterns of brain activity in response to swim stress assessment by 2-deoxyglucose uptake and expression of fos-like immunoreactivity. J Neurosci 13:3932–3934
Ebmeier KP, Donaghex C, Steele JD (2006) Recent developments and current controversies in depression. Lancet 367:153–167
Eckert A, Reiff J, Müller WE (1998) Arzneimittelinteraktionen mit Antidepressiva. Psychopharmakotherapie 5:8–18
Eckert A et al (2005) Stabilization of mitochondrial membrane potential and improvement of neuronal enery metabolism by Ginkgo bilobe Extrakt EGb 761. Ann N Y Acad Sci 1056:474–485
Ereshefsky L, Lacombe S (1993) Pharmacological profile of risperidone. Can J Psychiatry 38(Suppl 3):80–88
Erman MK (2005) Therapeutic options in the treatment of insomnia. J Clin Psychiatry 66(Suppl 9):18–23
Fone KCF, Nutt DJ (2005) Stimulants: use and abuse in the treatment of attention deficit hyperactivity disorder. Curr Opin Pharmacol 5:87–93
Frazer A (1997) Antidepressants. J Clin Psychiatry 58(Suppl 6):9–25
Fuchs E, Simon M, Schmelting B (2006) Pharmacology of a new antidepressant: benefit of the implication of the melatonergic system. Int Clin Psychopharmacol 21(suppl 1):S17–S20
Garbutt JC, West SL, Garey TS, Lohr KN, Crews FT (1999) Pharmacological treatment of alcohol dependence. JAMA 281:1318–1325
Gura T (2008) Hope in Alzheimer’s fight emerges from unexpected place. Nat Med 14(9):894
Haass C, Selkoe DJ (2007) Soluble protein oligomers in neurodegeneration: lessions form the Alzheimer’s amyloid β-peptide. Mol Cell Biol 8:101–112
Haefely W, Pöldinger W, Wider F (1983) Tranquilizer und Hypnotika: Grundlagen und Therapie. In: Langer G, Heimann H (Hrsg) Psychopharmaka, Grundlagen und Therapie. Springer, Wien/New York, S 301–346
Hauptmann S et al (2006) Mitochondrial dysfunction insporadic and genetic Alzheimer’s disease. Exp Gerontol 41:668–673
Henn FA, Vollmayr B (2004) Neurogenesis and depression. Etiology or epiphenomenon? Biol Psychiatry 56:146–150
Herdegen T, Tölle TR, Bähr M (Hrsg) (1997) Klinische Neurobiologie. Spektrum, Heidelberg
Holsboer F, Gründer G, Benkert O (Hrsg) (2008) Handbuch der Psychopharmakotherapie. Springer, Berlin
Hope BT, Kelz M, Duman RS, Nestler EJ (1994) Chronic electroconvulsive seizure (ECS) treatment results in expression of a long-lasting AP-1 complex in brain with altered composition and characteristics. J Neurosci 14:4318–4328
Jope RS, Williams MB (1994) Lithium and brain signal transduction systems. Biochem Pharmacol 47:429–441
Kapur S, Seeman P (2000) Antipsychotic agents differ in how fast they come off the dopamine D2 receptors. Implications for atypical antipsychotic action. J Psychiatry Neurosci 25:161–166
Kapur S, Seeman P (2001) Does fast dissociation from the dopamine D2 receptors explain the action of atypical antipsychotics? a new hypothesis. Am J Psychiatry 158:360–369
Keck PE, McElroy S (2005) Antieepileptic drugs. In: Schatzberg AF, Nemeroff CB (Hrsg) Textbuch of psychopharmacology, 2. Aufl. American Psychiatric Press, Washington, DC
Keil U et al (2006a) Piracetam improves mitochondrial dysfunction following oxidative stress. Br J Pharmacol 147:199–208
Keil U et al (2006b) Mitochondrial dysfunction induced by disease relevant AβPP and tau protein mutantions. J Alzheimers Dis 9:139–146
Kielholz P (1971) Diagnose und Therapie der Depression für den Praktiker, 3. Aufl. Lehmann, München
Klotz U, Laux G (1996) Tranquillantien Therapeutischer Einsatz und Pharmakologie, 2. Aufl. Wissenschaftliche Verlagsgesellschaft, Stuttgart
Lane RM (1996) Pharmacokinetic drug interaction potential of selective serotonin reuptake inhibitors. Int Clin Psychopharmacol 11(Suppl 5):31–61
Laux G, Dietmaier O (2012) Praktische Psychopharmakotherapie, 6. Aufl. Urban & Fischer, München
Lenox RH, Manji HK (2005) Lithium. In: Schatzberg AF, Nemeroff CB (Hrsg) Textbook of psychopharmacology, 2. Aufl. American Psychiatric Press, Washington, DC/London
Leonard BE (1995) Mechanisms of action of antidepressants. CNS Drugs 4(Suppl 1):1–12
Leonard BE (1996) New approaches to the treatment of depression. J Clin Psychiatry 57(Suppl 4):26–33
Leuner K, Müller WE (2007) Dopamine in the prefrontal cortex and its different modulation by conventionaland atypical antipsychotics. Pharmacopsychiatry 40(Suppl 1):17–26
Lin JH, Yamazaki M (2003) Role of P-glycoprotein in pharmacokinetics: clinical implications. Clin Pharmacokinet 42(1):59–98
Malberg JE, Blendy JA (2005) Antidepressant action: to the nucleus and beyond. Trends Pharmacol Sci 12:631–638
Malberg JE et al (2000) Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. J Neurosci 20:9104–9110
Manji HK, Moore GJ, Chen G (2000) Lithium up-regulates the cytoprotective protein Bcl-2 in the CNS in vitro: a role for neurotrophic and neuroprotective effects in manic depressive illness. J Clin Psychiatry 61(Suppl 9):82–96
Marchetti C, Tafi E, Middei S et al (2010) Synaptic adaptations of CA1 pyramidal neurons induced by a highly effective combinational antidepressant therapy. Biol Psychiatry 67(2):146–154
Mattson MP (2004) Pathways towards and away from Alzheimer’s disease. Nature 430:631–639
McEwen BS, Chattarji S, Diamond DM, Jay TM, Reagan LP, Svenningsson P, Fuchs E (2010) The neurobiological properties of tianeptine (Stablon): from monoamine hypothesis to glutamatergic modulation. Mol Psychiatry 15:237–249
Miyamoto S et al (2003) Recent advances in the neurobiology of schizophrenia. Mol Interv 3(1):27–29
Montgomery SA (1997) Is there a role for a pure noradrenergic drug in the treatment of depression? Eur Neuropsychopharmacol 7(Suppl 1):3–9
Morinobu S, Nibuya M, Duman RS (1995) Chronic antidepressant treatment down-regulates the induction of c-fos mRNA in response to acute stress in rat frontal cortex. Neuropschychopharmacology 12:221–228
Müller WE (1991) Wirkungsmechanismus niedrigdosierter Neuroleptika bei Angst und Depression. In: Pöldinger W (Hrsg) Niedrigdosierte Neuroleptika bei ängstlich-depressiven Zustandsbildern und psychosomatischen Erkrankungen. Braun, Karlsruhe, S 24–38
Müller WE (1995) Pharmacology of the GABAergic benzodiazepine system. In: Kales A (Hrsg) The pharmacology of sleep. Handbook of experimental pharmacology. Springer, Berlin/Heidelberg/New York/Tokio, S 211–242
Müller WE (1997a) Wie wirken die neueren Antidepressiva? Psychopharmakotherapie 4:2–5
Müller WE (1997b) Besonderheiten der Psychopharmakotherapie im Alter. In: Förstl H (Hrsg) Lehrbuch der Gerontopsychiatrie. Enke, Stuttgart, S 141–151
Müller WE (1998a) Pharmakologie und Neurobiochemie. In: Riederer P, Laux G, Pöldinger W (Hrsg) Neuro-Psychopharmaka. Ein Therapiehandbuch. Springer, Wien/New York, S 428–438
Müller WE (1998b) Rezeptorprofile erklären therapeutische und unerwünschte Wirkungen typischer und atypischer Neuroleptika. In: Rüther E, Bandelow B (Hrsg) Therapie mit klassischen Neuroleptika, heute und morgen. Springer, Berlin/Heidelberg/New York/Tokio, S 3–20
Müller WE (2002) Partieller D2-Agonismus und dopaminerge Stabilisierung durch Aripiprazol. Psychopharmakotherapie 9(4):120–127
Müller WE (2003) Current St. John’s wort research from mode of action to clinical efficacy. Pharmacol Res 47:101–109
Müller WE (2006) Entwicklungsperspektiven in der Psychopharmakologie. Die Psychiatrie 3:135–144
Müller WE (2013) Pharmakologie und Pharmakokinetik der in Deutschland gebräuchlichen Substanzen zur Behandlung der Alkoholabhängigkeit. Psychopharmakotherapie 20:209–219
Müller WE (2014) Therapeutische Anwendung von Aripiprazol-Depot. Psychopharmakotherapie 21:97–105
Müller WE (2015) Antidepressiva und kognitive Dysfunktion: die Rolle von Vortioxetin. Psychopharmakotherapie 22:177–188
Müller WE, Eckert A (1997) Pharmakodynamische Grundlagen der Therapie mit spezifischen Serotonin-Wiederaufnahmehemmern. Psychopharmakotherapie 4(Suppl 7):2–8
Müller WE, Mutschler E, Riederer P (1995) Noncompetitive NMDA receptor antagonists with fast open-channel blocking kinetics and strong voltage-dependency as potential therapeutic agents for Alzheimer’s dementia. Pharmacopsychiatry 28:113–124
Müller WE, Eckert A, Hartmann H et al (1996) Zur Kalziumhypothese der Hirnalterung. Nervenarzt 67:15–24
Mutschler J, Diehl A, Vollmert C et al (2008) Recent results in relaps prevention of alcoholism with Disulfiram. Neuropsychiatr 22:243–251
Nebert DW, Nelson DR, Coon MJ et al (1991) The P450 superfamily: update on new sequences, gene mapping, and recommended nomenclature. DNA Cell Biol 10:1–14
Nemeroff CB, Kinkead B, Goldstein J (2002) Quetiapine: preclinical studies, pharmacokinetics, drug interactions, and dosing. J Clin Psychiatry 63(Suppl 13):5–11
O’Brain CP (2005) Anticraving medications for relapse prevention: a possible new class of psychoactive medications. Am J Psychiatry 162:1423–1431
O’Brien FE, Dinan TG, Griffin BT, Cryan JF (2012) Interactions between antidepressants and P-glycoprotein at the blood–brain barrier: clinical significance of in vitro and in vivo findings. Br J Pharmacol 165(2):289–312
Otte C (2014) Depression und kognitive Dysfunktion. Psychopharmakotherapie 21:40–49
Paioni R, Waldmeier A, Delini-Stula A et al (1983) Antidepressiva: Grundlagen und Therapie. In: Langer G, Heimann H (Hrsg) Psychopharmaka. Grundlagen und Therapie. Springer, Wien/New York, S 57–159
Perry PJ, Alexander B, Liskow BI (1997) Psychotropic drug handbook. American Psychiatric Press, Washington, DC
Pittenger C, Duman R (2008) Stress, depression, and neuroplasticity: a convergence of mechanisms. Neuropsychopharmacology 33:88–109
Preskorn SH (1996) Clinical pharmacology of selective serotonin reuptake inhibitors. Professional Communications, Caddo
Preskorn SH, Magnus RD (1994) Inhibition of the hepatic P450 isoenzymes by serotonin selective reuptake inhibitors: in vitro and in vivo findings and their implications for patient care. Psychopharmacol Bull 30:251–259
Rajkowska G, Miguel-Hidalgo JJ, Wei J et al (1999) Morphometric evidence for neuronal and glial prefrontal cell pathology in major depression. Biol Psychiatry 45:1085–1098
Rappley MD (2005) Attention deficit-hyperactivity disorder. N Engl J Med 352(2):165–173
Reynolds PG (1996) The importance of dopamine D4 receptors in the action and development of antipsychotic agents. Drugs 51:7–11
Riederer P, Laux G, Pöldinger W (Hrsg) (2002–2010) Neuro-Psychopharmaka. Ein Therapie-Handbuch, 2. Aufl. Springer, Wien/New York
Riesenman C (1995) Antidepressant drug interactions and the cytochrome P450 system: a critical appraisal. Pharmacotherapy 15:84S–99S
Rollema H, Chambers LK, Coe JW, Glowa J et al (2007) Pharmacological profile of the α4β2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid. Neuropharmacology 52:985–994
Santarelli L et al (2003) Requirement of hippocampal neurogenesis for the behavioural effects of antidepressants. Science 301:805–809
Sapolsky RM (2004) Is impaired neurogenesis relevant to the affective symptoms of depression? Biol Psychiatry 56:137–139
Sapolsky RM, Krey LC, McEwen BS (1985) Prolonged glucocorticoid exposure reduces hippocampal neuron number: implications for aging. J Neurosci 5:1222–1227
Schatzberg AF, Nemeroff CB (2005) Textbook of psychopharmacology, 2. Aufl. American Psychiatric Press, Washington, DC
Schatzberg AF, Cole JO, DeBattista C (2010) Manual of clinical psychopharmacology, 7. Aufl. American Psychiatric Press, Washington, DC
Schüssel K, Müller WE (2007) Neue andere Wirkmechanismen. In: Volk HP, Gleiter CH (Hrsg) Antidementiva. Wissenschaftliche Verlagsgesellschaft, Stuttgart
Seeman P (1987) Dopamine receptors and the dopamine hypothesis of schizophrenia. Synapse 1:133–152
Seeman P (2005) An update of fast-off dopamine D2 atypical antipsychotics. Am J Psychiatry 162:1984–1985
Sills GJ (2006) The mechanisms of action of gabapentin und pregabalin. Curr Opin Pharmacol 6:108–113
Smith DF (1986) Wirkung von Lithium auf die Bewegungsaktivität von Versuchstieren. In: Müller-Oerlinghausen B, Greil W (Hrsg) Die Lithiumtherapie. Nutzen, Risiken, Alternativen. Springer, Berlin/Heidelberg/New York/Tokio, S 51–59
Soares JC, Mann JJ (1997) The anatomy of mood disorders – review of structural neuroimaging studies. Biol Psychiatry 41:86–106
Sokoloff P, Giros B, Martres MP et al (1990) Molecular cloning and characterization of novel dopamine receptor (D3) as a target for neuroleptics. Nature 347:146–151
Stassen HH, Angst J, Delini-Stula A (1996) Delayed onset action of antidepressant drugs? Survey of results of Zurich meta-analyses. Pharmacopsychiatry 29:87–96
Stone JM, Davis JM, Leucht S, Pilowsky LR (2009) Cortical dopamine D2/D3 receptors are a common site of action for antipsychotic drugs – an original patient data meta-analysis of the SPECT and PET in vivo receptor imaging literature. Schiziophr Bull 35:789–797
Stroup ST et al (2006) Clinical trials for antipsychotic drugs: design conventions, dilemmas and innovations. Nat Rev Drug Discov 5:133–146
Swerdlow RH, Burns JM, Khan SM (2010) The Alzheimer’s disease mitochondrial cascade hypothesis. J Alzheimers Dis 20(Suppl 2):S265–S279
Torres G, Horowitz JM, Laflamme N et al (1998) Fluoxetine induces the transcription of genes encoding c-fos, corticotropin-releasing factor and its type 1 receptor in rat brain. Neuroscience 87:463–477
Vaidya VA, Siuciak J, Du F, Duman RS (1999) Mossy fiber sprouting and synaptic reorganization induced by chronic administration of electroconvulsive seizure: role of BDNF. Neuroscience 89:157–166
Van Tol HHM, Bunzow JR, Guan HC et al (1991) Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine. Nature 350:610–614
Volkow ND, Swanson JM (2003) Variables that affect the clinical use and abuse of methylphenidate in the treatment of ADHD. Am J Psychiatry 160(11):1909–1918
Wadenbert MLG, Soliman A, Vanderspek SC, Kapur S (2001) Dopamine D2-receptor occupancy is a common mechanism underlying animal models of antipsychotics and their clinical effects. Neuropsychopharmacology 25:633–641
Watanabe Y, Gould E, Daniels DC, Cameron H, McEwen BS (1992) Tianeptine attenuates stress-induced morphological changes in the hippocampus. Eur J Pharmacol 222:157–162
Wedekind D, Bandelow B, Degner D (2005) Die α2δ-Untereinheit der spannungsabhängigen Kalziumkanäle. Nervenarzt 76:888–892
Willner P (1984) The validity of animal models of depression. Psychopharmacology (Berl) 83:1–16
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer-Verlag Berlin Heidelberg
About this entry
Cite this entry
Müller, W.E., Eckert, A. (2016). Psychopharmakotherapie – pharmakologische Grundlagen. In: Möller, HJ., Laux, G., Kapfhammer, HP. (eds) Psychiatrie, Psychosomatik, Psychotherapie. Springer Reference Medizin. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-45028-0_30-1
Download citation
DOI: https://doi.org/10.1007/978-3-642-45028-0_30-1
Received:
Accepted:
Published:
Publisher Name: Springer, Berlin, Heidelberg
Online ISBN: 978-3-642-45028-0
eBook Packages: Springer Referenz Medizin